Efficacy of high-frequency, low-intensity multipolar radiofrequency therapy for sensitive skin by modulating skin permeability barrier

Efficacy of high-frequency, low-intensity multipolar radiofrequency therapy for sensitive skin by modulating skin permeability barrier: A before-after control exploratory study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022866

Enrollment

Unknown

Registered

2019-04-28

Start date

2019-05-01

Completion date

Unknown

Last updated

2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sensitive skin

Interventions

Case series:High-frequency low-intensity radiofrequency therapy

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Otherwise healthy women aged between 18-65 years old; 2. Having self-perceived skin sensitivity stable over the past 6 months and cessation from drug treatment for at least 3 months; 3. Good compliance with treating protocol and follow-up.

Exclusion criteria

Exclusion criteria: 1. Having skin conditions that impede research such as eczema, seborrheic dermatitis, contact dermatitis, drug eruption, atopic dermatitis and lupus erythematous; 2. Having systemic conditions such as diabetes, epilepsy, heart failure, respiratory failure, impaired renal or liver function and tumors and SLE; 3. Having psychological conditions; 4. Receiving pacemaker or defibrillation treatments, or having hearing aid or metal implants in the body; 5. Not be able to avoid exacerbating factors during research; 6. Received dermabrasion or chemical peeling within 6 months or facial surgery within 3 months; 7. Pregnant or in lactation or anticipating pregnancy in 6 months; 8. Scar diathesis or malhealing history; 9. History of skin cancer; 10. Under topical steroid or retinoid treatments; 11. Having had anti-histamine drugs within 1 week, steroids or calcineurin inhibitors within 4 weeks; 12. Allergic to metals; 13. Currently participating other clinical trials; 14. Other conditions considered unsuitable for the research judged by the investigator.

Design outcomes

Secondary

Measure	Time frame
stratum corneum hydration;erythema index;DLQI;self-perceived skin sensitivity;	—

Primary

Measure	Time frame
clinical assessment score;lactic acid sting test;stratum corneum thickness;trans-epidermal water loss;	—

Countries

China

Contacts

Public ContactYan Shuxian

Department of Dermatology, Huashan Hospital Affiliated with the Shanghai Medical Collage of Fudan University

shuxianyan0225@126.com+86 13817200326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026